| 1. |
- Bersani, Cinzia, et al.
(författare)
-
A model using concomitant markers for predicting outcome in human papillomavirus positive oropharyngeal cancer
- 2017
-
Ingår i: Oral Oncology. - : Elsevier. - 1368-8375 .- 1879-0593. ; 68, s. 53-59
-
Tidskriftsartikel (refereegranskat)abstract
- Objective: Head-neck cancer therapy has become intensified. With radiotherapy alone, 3-year disease-free survival (DFS) is 80% for HPV-positive TSCC/BOTSCC and better for patients with favorable characteristics, suggesting therapy could be tapered for some, decreasing side-effects. Therefore, we built a model to predict progression-free survival for patients with HPV-positive TSCC and BOTSCC. Material and methods: TSCC/BOTSCC patients treated curatively between 2000 and 2011, with HPV16 DNA/E7 mRNA positive tumors examined for CD8(+) TILs, HPV16 mRNA and HLA class I expression were included. Patients were split randomly 65/35 into training and validation sets, and LASSO regression was used to select a model in the training set, the performance of which was evaluated in the validation set. Results: 258 patients with HPV DNA/E7 mRNA positive tumors could be included, 168 and 90 patients in the respective sets. No treatment improved prognosis compared to radiotherapy alone. CD8(+) TIL counts and young age were the strongest predictors of survival, followed by T-stage <3 and presence of HPV16 E2 mRNA. The model had an area under curve (AUC) of 76%. A model where the presence of three of four of these markers defined good prognosis captured 56% of non-relapsing patients with a positive predictive value of 98% in the validation set. Furthermore, the model identified 35% of our cohort that was over-treated and could safely have received de-escalated therapy. Conclusion: CD8(+) TIL counts, age, T-stage and E2 expression could predict progression-free survival, identifying patients eligible for randomized trials with milder treatment, potentially reducing side effects without worsening prognosis.
|
|
| 2. |
- Grün, Nathalie, et al.
(författare)
-
Human papillomavirus prevalence in mouthwashes of patients undergoing tonsillectomy shows dominance of HPV69, without the corresponding finding in the tonsils.
- 2017
-
Ingår i: Infectious diseases (London, England). - : Informa UK Limited. - 2374-4243 .- 2374-4235. ; 49:8, s. 588-593
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: The role of human papillomavirus (HPV) in tonsillar squamous cell carcinomas (TSCC) is of interest, since a considerable proportion of TSCC in Sweden and other Western countries is HPV positive. Nevertheless, the natural history of HPV in normal tonsils, and the progression from localized infection to pre-malignant lesion to cancer are poorly understood. The aim of this study was to investigate whether HPV types found in mouthwash samples correlated to those in tonsillar tissue from the same individuals undergoing tonsillectomy.METHODS: Mouthwash samples from 232 patients, aged 3-56 years, undergoing tonsillectomy, the majority with chronic tonsillitis, were collected at the time of surgery and analysed for the presence of 27 HPV types by a bead based multiplex assay.RESULTS: An HPV prevalence of 10.3% (24/232) was observed in mouthwash samples, with HPV 69 being the dominant type (10/24). Ten patients were positive for high risk HPV (HPV 16, 33, 35, 45, 56, 59). None of the tonsils resected from patients with HPV-positive mouthwash samples were positive for HPV.CONCLUSIONS: Despite an oral HPV prevalence of 10.3% in mouthwash samples from tonsillectomized patients, with dominance of HPV 69, none of the corresponding tonsillar samples exhibited the presence of HPV.
|
|
| 3. |
- Hou Grün, Nathalie
(författare)
-
Human papillomavirus infection in healthy youth and in hypopharyngeal cancer
- 2016
-
Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
- The aim of this thesis was to follow the prevalence of human papillomavirus in the oral cavity and in the cervix in youth during the period of 2008-2015, a period when HPV vaccination was gradually introduced to young girls in Sweden. In addition, we explored the prevalence of HPV in hypopharyngeal cancer during the period 2000-2012 on the basis that there has been an epidemic of HPV positive tonsillar and base of tongue cancer, which arise in locations with close physiological proximity to the hypopharynx. The main questions addressed were whether HPV prevalence is similar within different cohorts of Swedish youth, how the prevalence changes over time and after the introduction of the HPV vaccines, and if the increased proportion of HPV positive oropharyngeal cancer is mirrored also in hypopharyngeal cancer. Since the prevalence of oral and genital HPV previously observed at a Stockholm youth clinic was high during the period of 2008-2011, there was an opportunity to compare these data to the HPV prevalence in different geographical locations and at other time points. The strong Swedish tradition of biobanking granted access to a relatively large sample of hypopharyngeal cancers, and the high prevalence of HPV in oropharyngeal cancers in Sweden made it credible that HPV would also be present at detectable levels in hypopharyngeal cancer and make it possible to detect changes occurring in the HPV prevalence in this cancer type. To investigate these matters, oral and cervical samples were analyzed for the presence of HPV DNA, a questionnaire was used to investigate the sexual experiences of youth, and HPV DNA and p16 expression was analyzed in relation to survival in samples of hypopharyngeal cancer. In Paper I, we could show that oral HPV prevalence was significantly less common in high school students from a middle sized municipality in Sweden (1.8%) than what was observed in 2009-2011 in the Stockholm youth clinic(9.3%). In Paper II, we could show that there were no differences between HPV vaccinated and nonvaccinated women regarding condom use and self-reported STI history, however, vaccinated women were more likely to have had vaginal intercourse and one-night stands (p=0.005, and p=0.046, respectively). In Paper III, we found a low oral HPV prevalence also at the Stockholm youth clinic (1.4%) in 2013-2014 which was lower than what was previously observed at the same clinic (p=0.00001). Cervical HPV 16, 31 and 70 prevalence was now less common in vaccinated than in non-vaccinated individuals (p =0.0002, p=0.019, and p=0.006, respectively). In Paper IV, we expanded the cohort from paper 3 to also include samples from the fall of 2014 and the spring of 2015. Oral HPV prevalence remained low (1.5%) and cervical HPV 16, 31 and 6 were less common in vaccinated than in non-vaccinated women (p=0.0006, p=0.038 and p=0.009, respectively). In Paper V, we could show that the proportion of HPV positive cases of hypopharyngeal cancer have not increased in Stockholm and that p16 is a poor surrogate marker of active HPV infection in this cancer type.
|
|
| 4. |
- Nordfors, Cecilia, et al.
(författare)
-
Oral human papillomavirus prevalence in high school students of one municipality in Sweden
- 2013
-
Ingår i: Scandinavian Journal of Infectious Diseases. - : Informa UK Limited. - 0036-5548 .- 1651-1980. ; 45:11, s. 878-881
-
Tidskriftsartikel (refereegranskat)abstract
- The rise in human papillomavirus (HPV) infection has been suggested to be responsible for the increased incidence of oropharyngeal cancer in the Western world. This has boosted interest in oral HPV prevalence and whether HPV vaccines can prevent oral HPV infection. In a previous study we showed oral HPV prevalenceto be almost 10% in youth aged 15-23 y attending a youth clinic in Stockholm, Sweden. However, this may not be a generalizable sample within the Swedish population. Therefore, mouthwashes were used to investigate oral HPV prevalence in 335 Swedish high school students aged 17-21 y (median age 18 y), from 1municipality with 140,000 inhabitants. The presence of HPV DNA in the oral samples, as examined by a Luminex-based assay, was significantly lower in this cohort, only 1.8% (3.1% in females and 0.6% in males), as compared to our previous study.
|
|
| 5. |
- Näsman, Anders, et al.
(författare)
-
Absent/weak CD44 intensity and positive human papillomavirus (HPV) status in oropharyngeal squamous cell carcinoma indicates a very high survival
- 2013
-
Ingår i: Cancer Medicine. - : John Wiley & Sons. - 2045-7634. ; 2:4, s. 507-18
-
Tidskriftsartikel (refereegranskat)abstract
- Patients with human papillomavirus DNA positive (HPVDNA+) oropharyngeal squamous cell carcinoma (OSCC) have better clinical outcome than those with HPV DNA negative (HPVDNA-) OSCC upon intensive oncological treatment. All HPVDNA+ OSCC patients may not require intensive treatment, however, but before potentially deintensifying treatment, additional predictive markers are needed. Here, we examined HPV, p16(INK4a), and CD44 in OSCC in correlation to clinical outcome. Pretreatment tumors from 290 OSCC patients, the majority not receiving chemotherapy, were analyzed for HPV DNA by Luminex and for p16(INK4a) and CD44 by immunohistochemistry. 225/290 (78%) tumors were HPVDNA+ and 211/290 (73%) overexpressed p16(INK4a), which correlated to presence of HPV (P < 0.0001). Presence of HPV DNA, absent/weak CD44 intensity staining correlated to favorable 3-year disease-free survival (DFS) and overall survival (OS) by univariate and multivariate analysis, and likewise for p16(INK4a) by univariate analysis. Upon stratification for HPV, HPVDNA+ OSCC with absent/weak CD44 intensity presented the significantly best 3-year DFS and OS, with >95% 3-year DFS and OS. Furthermore, in HPVDNA+ OSCC, p16(INK4a)+ overexpression correlated to a favorable 3-year OS. In conclusion, patients with HPVDNA+ and absent/weak CD44 intensity OSCC presented the best survival and this marker combination could possibly be used for selecting patients for tailored deintensified treatment in prospective clinical trials. Absence of/weak CD44 or presence of human papillomavirus (HPV) DNA was shown as a favorable prognostic factors in tonsillar and tongue base cancer. Moreover, patients with the combination of absence of/weak CD44 and presence of HPV DNA presented a very favorable outcome. Therefore, we suggest that this marker combination could potentially be used to single out patients with a high survival that could benefit from a de-escalated oncological treatment.
|
|
| 6. |
- Sivars, Lars, et al.
(författare)
-
Human papillomavirus DNA detection in fine-needle aspirates as indicator of human papillomavirus-positive oropharyngeal squamous cell carcinoma : A prospective study
- 2017
-
Ingår i: Head and Neck. - : Wiley. - 1043-3074 .- 1097-0347. ; 39:3, s. 419-426
-
Tidskriftsartikel (refereegranskat)abstract
- Background. Human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (SCC) has a better outcome than most head neck squamous cell carcinomas (HNSCCs) and an HPV-positive lymph node metastasis likely has an HPV-positive oropharyngeal SCC origin. Determining HPV-status in cervical lymph nodes by fine-needle aspiration cytology (FNAC) may be useful for diagnosis. Methods. FNACs from 66 patients with neck masses were prospectively examined for HPV DNA and HPV16 mRNA by a polymerase chain reaction (PCR)-based assay, and the data correlated to diagnosis and HPV-status obtained from histopathological specimens. Results. Aspirates from 17 of 66 patients, later diagnosed with HPV-positive oropharyngeal SCC, were HPV16 DNA-positive. HPV16 mRNA was detected in all cases with extractable RNA. All remaining FNACs, including 18 branchial cleft cysts, were HPV DNA-negative. HPV DNA status in the aspirates showed perfect concordance with corresponding biopsies. Conclusion. HPV16 DNA detection in fine-needle aspirations from neck masses is reliable and HPV16 DNA in a metastasis is a strong indicator of an HPV-positive oropharyngeal SCC.
|
|
